Operating Expenses
Total Operating Expenses
Alnylam Pharmaceuticals Total Operating Expenses decreased by 6.9% to $898.54M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 56.0%, from $576.11M to $898.54M. Over 4 years (FY 2021 to FY 2025), Total Operating Expenses shows an upward trend with a 19.9% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID:
total_operating_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $366.71M | $369.31M | $453.10M | $359.99M | $416.50M | $522.35M | $523.65M | $469.10M | $548.59M | $536.66M | $556.12M | $537.77M | $611.21M | $577.82M | $698.33M | $576.11M | $789.89M | $881.04M | $965.32M | $898.54M |
| QoQ Change | — | +0.7% | +22.7% | -20.5% | +15.7% | +25.4% | +0.2% | -10.4% | +16.9% | -2.2% | +3.6% | -3.3% | +13.7% | -5.5% | +20.9% | -17.5% | +37.1% | +11.5% | +9.6% | -6.9% |
| YoY Change | — | — | — | — | +13.6% | +41.4% | +15.6% | +30.3% | +31.7% | +2.7% | +6.2% | +14.6% | +11.4% | +7.7% | +25.6% | +7.1% | +29.2% | +52.5% | +38.2% | +56.0% |
Range$359.99M – $965.32M
CAGR+20.8%
Avg YoY Growth+24.0%
Median YoY Growth+20.6%
Total Operating Expenses at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's total operating expenses?
- Alnylam Pharmaceuticals (ALNY) reported total operating expenses of $898.54M in Q1 2026.
- How has Alnylam Pharmaceuticals's total operating expenses changed year-over-year?
- Alnylam Pharmaceuticals's total operating expenses increased by 56.0% year-over-year, from $576.11M to $898.54M.
- What is the long-term trend for Alnylam Pharmaceuticals's total operating expenses?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's total operating expenses has grown at a 19.9% compound annual growth rate (CAGR), from $1.55B to $3.21B.